® ® ® th th 1990: • Idea of MARS (Molecular Adsorbents Recirculating System) 1991: •MARS therapy: First patent filed 1992: • Jan Stange receives Grant for Artifical Liver 1993: •Continuation in part patent filed 1997: • Foundation of Society for Extracorporeal Detoxication (VED) e.V. 1999: • Biopure Medizinprodukte GmbH & TERAKLIN GmbH merge to TERAKLIN AG 2000: • 40 centers used a MARS therapy 2007: • Establishment of ARTCLINE GmbH 12 March 2008: • Foundation of competence network „CEOS“ 2011: •Foundation of Fraunhofer Group „EXIM“ - Extracorporeal Immunomodulation 2013: • 13 ISAD as part of European Society for Artificial Organs (ESAO) formed at the Meeting “Artificial Liver Support” in Celle, by J. Stange and W. Ramlow (2 Mio DM by BMBF) and founds group by J. Stange, Steffen Mitzner and W. Ramlow • Establishment of Biopure Medizinprodukte GmbH & TERAKLIN GmbH •1st MARS® monitor with standardized sets for the MARS© therapy • Dr. Jan Stange moved to the United States; - Center for Extracorporeal Organ Support, Rostock - Congress in Rostock attended to multicenter study with 70 patients 2012: • Conception growth core „Support Center for Organ & Recovery“ in Rostock Germany by Students and Mentors of Rostock with Steffen Mitzner in Rostock •1st MARS®- treatment at the Department of •National Champion „Biopure GmbH“ - •1st International Symposium on Albumin Dialysis (ISAD) in Rostock Internal Medicine, University of Rostock Entrepreneurs Competition „Start Up 1997“ ® 2001: • Nomination of MARS therapy for German Future Prize RTC Stemcells, Montag, 14.03.2011 Experimentelle Chirurgie PROGRAMM Verbund 3: Organ Regeneration Gründung der Fraunhofer-Gruppe ELIMINATION OF TOXINS 2002: • TERAKLIN AG: approvals in India, Australia, South Korea and Taiwan „Extrakorporale Immunmodulation“ EXIM Support Seracell AG ® Zentrum • TERAKLIN AG: application for approval of MARS in the USA at the Food and Drug CEOS BMBF-Innovationsforum „Bioaktive Zellfilter“ Klinische Forschung, 3 Forschungsdialyse Center for Extracorporeal Organ Support Regeneration Zellbiologie Institut Elektrotechnik Administration (FDA) at the end of the year Verbund 1: Verbund 5: Organ Support-Human- Organ Support Hardware Interface Center for Bluepoint Medical Montag, 14.03.2011 Dialysis against a recycled albumin solution Organ Support Artcline GmbH GmbH & CoKG ® . In: J Artif Organs 1993; 17: 809–813. Cases of patients treated with MARS© therapy AwardsGründung der Fraunhofer-Gruppe 15:00 - 16:30 WS2 Zellaufbereitung und Zelllagerung and Regeneration Impulsvortrag: PD Dr. Hans-Gert Heuft Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H.: 1 5 „Extrakorporale Immunmodulation“ EXIM Medizinische Hochschule Hannover, Institut für Transfusionsmedizin enables the removal of albumin-bound toxins (FLD e.V.) th ® A carrier-mediated transport of toxins in a hybridMolecular membrane. adsorbent Safety barrierrecycling bet- sys- Diskussion 15 October 2003 : • MARS in ordinance on case payments for 2004 - catalog, D The MARS08:30 – 09:30 Pressekonferenz® therapy has been honored with 17 na- Stange J, Mitzner S.: 09:30 – 11:00 Eröffnung und feierliche Vertragsunterzeichnung 16:30 - 17:00 Kaffee ween a patients blood and a bioartificial liver. In: J Artif Organs 1996; 19: 677–691. ACUTE DECOMPENSATION OF CHRONIC LIVER DISEASE Minister Henry Tesch tional and international awards17:00 - 18:30 (list:WS3 Bioaktive extract Filter in der Bio-, on Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, et al.: Ministerium für Bildung, Wissenschaft und Kultur MV Transfusionsmedizin Universitätsklinik tem (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver Lebensmittel- und Umwelttechnologie : J Artif Organs 1999; 23: 319–330. Improvement of hepatorenal syn- Prof. Dr. Frank Emmrich support.In Universitätsklinik Öffentlich-private Partnerschaft Dagmar Heinicke, 40 years, first MARS® patient, jaundice awards). Direktor des Fraunhofer-Institutes für Zelltherapie und Immunologie Leipzig Impulsvortrag: Prof. Dr. Thomas Groth im Biomedizinischen Forschungszentrum Rostock y Martin-Luther-Universität Halle-Wittenberg, AG Biomedizinische Materialien The Histor of MARS Verbund 4: Verbund 2: ® Prof. Dr. Wolfgang Schareck Steffen R. Mitzner, Jan Stange, Sebastian Klammt, Teut Risler, Christiane M. Erley, Brigitte D. Bader, Elke 2004: • MARS in catalogs of the defined benefit hospital financing system, Austria - admission to the Department of Internal Medicine Rostock; falls into a coma Rektor der Universität Rostock Diskussion D. Berger, Werner Lauchart, Piotr Peszynski, Jens Freytag, Heiko Hickstein, Jan Loock, Johannes-Mathias Immune Modulation Organ Support Disposables Center for Organ Support Prof. Dr. Emil C. Reisinger Löhr, Stefan Liebe, Jörg Emmrich, Gero Korten and Reinhard Schmidt: - As part of MARSDekan der Med. Fakultät der Universität® external Rostock funding18:30 - 19:00 Abschlussdiskussion investments of drome with extracorporealIn: Liver Transplantation,Volume albumin dialysis mars: 6, Issue Results 3, May of 2000,a prospective, Pages: 277–286. randomized, - Studie: controlled Tübingen/ Fraunhofer AG EXIM and Regeneration MARS clinical trial. MEMBRANE Prof. Dr. Steffen Mitzner Moderation Prof. Dr. Udo Kragl Artcline GmbH Albutec GmbH - cause: chronic hepatitis C with acute decompensation of liver function HRO CEOS – “from Science to Clinic” • Establishment of Albutec GmbH Leiter der AG EXIM Universität Rostock, Interdisziplinäre Fakultät 10 million11:00-11:30 Rundgangeuros as well as industrial investments of Jan Stange, Steffen R. Mitzner, Sebastian Klammt, Jens Freytag, Piotr Peszynski, Jan Loock, Heiko Hick- 4 2 20:00 Abendveranstaltung (separate Einladung) - after the second day of the MARS® treatment: patient wakes up from coma 11:30-12:30 Buffet stein, Gero Korten, Reinhardt Schmidt, Jörg Hentschel, Martin Schulz, Matthias Löhr, Stefan Liebe, Wolf- gang Schareck and Ullrich T. Hopt: Liver support by extracorporeal blood purification: A clinical obser 30 million euros were acquired. vation. In: Liver Transplantation,Volume 6, Issue 5, September 2000, Pages: 603–613. - discharge from hospital after several MARS® treatments (preparation LTx) BMBF-Innovationsforum „Bioaktive Zellfilter“ Dienstag, 15.03.2011 Molecular Adsorbents Recirculating System • 09/2004 Acquisition of TERAKLIN AG by Gambro Steffen R. Mitzner,Improvement Sebastian Klammt,of Multiple Piotr Organ Peszynski, Functions Heiko in Hickstein, Hepatorenal Gero Syndrome Korten, Jan During Stange Albumin and Rein- Verbunde 1- 5 12:30 - 13:00 Eröffnung Innovationsforum Workshop der Studiengruppe EISS-2 hard Schmidt: • 1991: PromotionManfred Hempe of MARS® in the programme Dialysis with the Molecular Adsorbent Recirculating System. In: Therapeutic Apheresis,Volume 5, Issue Für das Bundesministerium für Bildung und Forschung Studienprotokolle für extrakorporale Zelltherapien 5, October 2001, Pages: 417–422. Dr. Jens Altrichter 09:00 - 10:30 I. Medizinische Grundlagen ‚PromotingGeschäftsführer derJunior Artcline GmbH Biotechnology Groups in East Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS.: Hemodynamic changes during a single Impulsvortrag: Dr. Martin Sauer treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver MARS® FLUX DIALYZER diaMARS® ADSORPTION dia FLUX DIALYZER ® 13:00 - 18:30 Themen - Workshops MULTIORGAN FAILURE Universität Rostock, Klinik für Anästhesiologie und Intensivtherapie failure. Liver Transpl 2001; 7: 1034–1039. COLUMNS 2005: • MARS approval in the USA 13:00 - 14:30 WS1 Zellen in extrakorporalen Diskussion MARS®-Therapie Germany‘, DM 2 million, 5 years Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, therapeutischen Anwendungen 10:30 - 11:00 Kaffeepause Heemann U, Treichel U, Loock J, Philipp T, GerkenG, Malago M, Klammt S, Loehr M, Liebe S, Mitrzner S, The procedure of the MARS®-therapy - 8-year-old girl with no anamnesis - admission to the Department of Cardiology Schmidt R, Stange J: Impulsvortrag: Prof. Dr. Jörg Vienken 11:00 - 12:30 II. Praktische Umsetzung controlled study. In: Hepatology (2002), 36, S.949-958. - Studie: Essen/HRO Fresenius Medical Care AG MARS The MARS® system removes protein-bound and water-soluble toxins with albumin dialysis. Trans- • January 1994: Dr. Jan Stange Impulsvortrag: Prof. Dr. Michael Bauer The ® therapy has caused a revolution in the field of liver therapy. The blood detoxification process helps to clean the liver - diagnosis: myocarditis, consequence: cardiac arrhythmia + cardiac arrest with the conse Diskussion Universität Jena, Klinik für Anästhesiologie und Intensivtherapie Steiner C, Mitzner S.: Experiences with MARS liver support therapy in liver failure: analysis of 176 pa- Diskussion tients of the International MARS Registry. In: Liver,Volume 22, Issue Supplement s2, April 2002, Pages: 14:30 - 15:00 Kaffee 20–25. outside the body. With this method water-soluble and water-insoluble protein-bound liver toxins are removed from the patient’s port proteins with free binding sites lure behind the MARS®-membrane and remove the toxins quence of cardiogenic shock and multi-organ failure - research grant by the Sandoz Foundation in Novelli G, Rossi M, Pretagostini R, Poli L, Novelli L, Berloco, P, Ferretti G, Lappelli M, Cortesini R: MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of acute liver failure. In: blood. from the blood. Toxin-removing material as the human serum albumin (HSA) is used.